Younger cancer survivors were more likely than their older peers to start alcohol use disorder treatment within 1 year of diagnosis. Less than 15% of cancer survivors diagnosed with alcohol use ...

Pediatric patients with diffuse midline gliomas may have better outcomes if they have a more diverse gut microbiome.

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.

The FDA has granted de novo authorization to CLAIRITY BREAST, a platform that uses AI to help predict a woman's risk of breast cancer.

(HealthDay News) — Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published in JAMA Oncology.

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

The number of cancer survivors in the United States reached 18.6 million as of January 1 this year and is projected to exceed 22 million by 2035.

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...